By Dean Seal

Shares of Pulse Biosciences hit a two-year high after regulators granted breakthrough device designation for Pulse's cardiac surgery system for the ablation of cardiac tissue during atrial fibrillation.

The stock rose 28% to a high of $15.43 in early trading. Shares haven't traded this high since January 2022.

Breakthrough device designation is granted to devices that may provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions for which no approved alternative exists.

The Miami-based company said Monday that the Food and Drug Administration's special designation would help it seek premarket approval for the system in the treatment of atrial fibrillation.

Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

07-08-24 1119ET